Biofrontera Inc reports results for the quarter ended December 31 - Earnings Summary
21/03/2025 13:31
Biofrontera Inc BFRI.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.80. The mean expectation of two analysts for the quarter was for a loss of 2 cents per share. Wall Street expected results to range from -7 cents to 2 cents per share. Revenue rose 18.5% to $12.56 million from a year ago; analysts expected $14.53 million. Biofrontera Inc's reported EPS for the quarter was a loss of 25 cents. The company reported a quarterly loss of $1.4 million. Biofrontera Inc shares had fallen by 5.5% this quarter. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Biofrontera Inc is $11.50 This summary was machine generated from LSEG data March 21 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.02 | -0.25 | Missed |
| Sep. 30 2024 | -0.83 | -0.98 | Missed |
| Jun. 30 2024 | -0.77 | -0.05 | Beat |
| Mar. 31 2024 | -1.17 | -2.88 | Missed |
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales